RxDoctor Payments Data

Yasmin Alaran

Physician Assistant · Downey, CANPI 1962045922

Payments from drug & device makers

$4,473in general payments, 2019–2025

Across 157 payments — averaging $28.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$453
  • Johnson & Johnson$392
  • Teleflex LLC$364
  • Bayer$323
  • AbbVie$316
  • Axonics, Inc.$310
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,17193%
  • Education$3027%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,473 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$36,302
Medicare patients
165
Services billed
1,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron226$201,575
OrgovyxRelugolix64$167,077
Abiraterone Acetate12$64,042
MyrbetriqMirabegron73$60,994
PremarinEstrogens, Conjugated28$11,806
Tamsulosin Hcl586$8,942
Tolterodine Tartrate ErTolterodine Tartrate36$6,731
Finasteride318$4,308
Solifenacin Succinate70$4,182
Methenamine Hippurate24$2,392
Oxybutynin Chloride ErOxybutynin Chloride96$1,982
Alfuzosin Hcl ErAlfuzosin Hcl84$1,907
Estradiol25$1,263
Trospium Chloride14$765
Cephalexin59$425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$453$368,652290 claims
Astellas Pharma US IncMyrbetriq$248$60,99473 claims
PfizerPremarin$138$11,80628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →